Concepedia

Publication | Closed Access

Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC

DOI

546

Citations

30

References

2023

Year

Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su,
New England Journal of Medicine

Abstract

Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, <i>EGFR</i>-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

References

YearCitations

Page 1